Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Debt: 2014-2025

Historic Total Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 7 years, with Sep 2025 value amounting to $20.9 million.

  • Viridian Therapeutics, Inc.\DE's Total Debt rose 1.79% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 1.79%. This contributed to the annual value of $20.6 million for FY2024, which is 1.87% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Total Debt of $20.9 million as of Q3 2025, which was up 0.49% from $20.8 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Total Debt's 5-year high stood at $20.9 million during Q3 2025, with a 5-year trough of $20.2 million in Q4 2023.
  • Its 3-year average for Total Debt is $20.6 million, with a median of $20.6 million in 2024.
  • Data for Viridian Therapeutics, Inc.\DE's Total Debt shows a peak YoY grew of 1.87% (in 2024) over the last 5 years.
  • Viridian Therapeutics, Inc.\DE's Total Debt (Quarterly) stood at $20.2 million in 2023, then climbed by 1.87% to $20.6 million in 2024, then increased by 1.79% to $20.9 million in 2025.
  • Its Total Debt stands at $20.9 million for Q3 2025, versus $20.8 million for Q2 2025 and $20.7 million for Q1 2025.